Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the researchers synthesized copper-doped mesoporous silica nanoparticles and observed that they enhance tumor microenvironment regulation and, when paired with disulfiram, effectively kill cancer cells while also showing synergistic anti-tumor effects with immune checkpoint inhibitors.

This article discusses ongoing and planned clinical chemoprevention trials for various agents and combinations but reports no new results; it highlights promising new agents and the evolving focus on molecular pathways.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

This study outlines new strategies for overcoming "cold" tumors, which are typically unresponsive to cancer immunotherapy, with approaches like dendritic cell-based treatments and local immune microenvironment modification, bolstered by both preclinical and clinical trial data.

This review discusses the role of phytochemical nanoparticles in cervical cancer therapy and reports no new clinical results; the authors highlight their potential advantages over conventional chemotherapy.

This review examines the incidence and management of dermatologic adverse effects from FDA-approved oral targeted cancer therapies, highlighting frequent occurrences like rashes and rarer severe conditions such as Stevens-Johnson Syndrome.

This review reports that the compound Cepharanthine shows promise as a cancer therapy by inducing cell death, arresting cell growth, inhibiting tumor progression, modulating key oncogenic pathways, and reversing multidrug resistance, suggesting its potential for further investigation in oncology.

This review highlights the potential of herbal remedies as complementary options for breast cancer care, noting benefits like immune modulation and reduced chemotherapy side effects, in contrast to conventional treatments that often cause significant side effects and long-term health issues.

This study synthesized new heterocyclic steroid derivatives and reported their promising antiproliferative activity against breast and prostate cancer cell lines, highlighting selectivity and impact on signaling pathways even in cells resistant to certain treatments.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

This study found that low-dose methotrexate significantly reduced the steroid requirement in subjects with corticosteroid-requiring asthma without altering their clinical status or causing significant complications.

This phase II study found that gemcitabine plus paclitaxel showed promising activity and manageable toxicity as first-line therapy for recurrent or metastatic breast cancer, with a 35% overall response rate.

This case study details the successful use of metyrapone to manage severe Cushing’s disease symptoms and stabilize a patient’s biochemical parameters before she underwent pituitary surgery.

This study discusses various anti-cancer therapies, including chemotherapy and immunotherapy, emphasizing the challenges in classifying these medications due to their diverse chemical compositions, mechanisms of action, and effectiveness against different types of cancer.

This study observed that MIRV improved gastrointestinal symptoms and other quality of life measures in patients with platinum-resistant ovarian cancer compared to chemotherapy.

This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.

This study reported that a gemcitabine and pemetrexed regimen was moderately active in advanced NSCLC but did not offer an advantage over the paclitaxel and gemcitabine regimen and is not recommended for further evaluation.

This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.

The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.

This study found that metyrapone and etomidate provide dose-dependent anticonvulsant effects against seizures, with delayed effectiveness linked to increased neurosteroid levels.

This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.

In this study, researchers developed and tested a novel peptide, AMHR2BP, which mimics the function of Anti-Müllerian hormone to protect ovarian follicles in mice, showing promise for preserving ovarian health during chemotherapy without causing toxicity.

In this study, pemetrexed combined with cisplatin for advanced NSCLC treatment had similar efficacy to gemcitabine but resulted in significantly fewer adverse reactions.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This review discusses preclinical and clinical chemoprevention research for several cancers, noting challenges in effectiveness and toxicity, and emphasizes the need for further trials.

This case report describes a 19-year-old patient with microsatellite stable adrenocortical carcinoma who showed a promising 36-month response to pembrolizumab, including structural and biochemical improvements, with primary adrenal insufficiency as a major side effect.

This review highlights the potential of Sacituzumab Tirumotecan, an antibody-drug conjugate, in treating gynecologic cancers, with ongoing Phase III trials indicating a manageable safety profile and future results expected to shed light on its effectiveness in improving survival and response rates.

This review synthesizes current evidence on the Warburg effect in anaplastic thyroid carcinoma and discusses potential therapeutic targets, but reports no new clinical results.